SUPERNUS PHARMACEUTICALS, INC. cotiza a 42.81 USD y tiene una capitalización bursátil de $2.5B. En los últimos 12 meses ha facturado $830M con un margen de flujo de caja libre del 6.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GO…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.53 | $0.21 | $0.88 |
| Estimado | $0.62 | $0.51 | $0.28 | $0.28 |
| Sorpresa | — | +3.9% | -25.0% | +214.3% |
| Métrica | SUPN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 89.6% | 57.0% | +32.6% |
| Operating Margin | -8.7% | -38.6% | +30.0% |
| Net Margin | -5.4% | -33.6% | +28.2% |
| FCF Margin | 6.4% | -13.9% | +20.3% |
| ROE | -3.6% | -40.4% | +36.8% |
| ROA | -2.6% | -32.0% | +29.4% |
| Current Ratio | 1.90 | 2.84 | -0.94 |
| Debt / Equity | — | 0.28 | — |